Reference | Adverse reactions by number of patients at risk (adverse reactions/number of patients) % | Adverse reactions by number of AIT injections (adverse reactions/number of injections*) % | ||
---|---|---|---|---|
Local reactions | Systemic reactions | Local reactions | Systemic reactions | |
Solá, 2018 | (60/110) 54.5 (95% CI 44.8–64) | (9/110) 8.2 (95% CI 3.8–15) | (60/110*(6 + 12)) 3.03 (95% CI 2.3–3.9) | (9/110*(6 + 12)) 0.46 (95% CI 0.2–0.9) |
Walker, 2001 [7] | (0/22) 0 | (4/22) 18.2 | (0/22*(11 + 11)) 0 | (4/22*(11 + 11)) 0.8 |
Crimi, 2004 [9] | (3/15) 20 | (0/15) 0 | (3/15*(12 + 10)) 0.9 | (0/15*(12 + 10)) 0 |
Nanda, 2004 [10] | (0/20) 0 | (1/20) 5 | (0/20*(9 + 11)) 0 | (1/20*(9 + 11)) 0.3 |
Tabar, 2005 [11] | (7/120) 5.8 | (4/120) 3.3 | (7/120*(16 + 11)) 0.2 | (4/120*(16 + 11)) 0.1 |
Colás, 2006 [13] | (16/41) 39 | (16/41) 39 | (16/41*(7 + 12)) 2.1 | (16/41*(7 + 12)) 2.1 |
Subiza, 2008 [14] | (7/22) 31.8 | (0/22) 0 | (7/22*(5 + 12)) 1.9 | (0/22*(5 + 12)) 0 |
Zhang, 2009 [16] | (18/45) 40 | (5/45) 11.1 | (18/45*(14 + 11)) 1.6 | (5/45*(14 + 11)) 0.4 |
Lou, 2012 [17] | – | – | – | – |
Klimek, 2014 [18] | (7/61) 11.5 | (5/61) 8.2 | (7/61*(5 + 11)) 0.7 | (5/61*(5 + 11)) 0.5 |
González-Gutiérrez, 2012 [6] | (32/127) 25.2 | (14/127) 11 | (32/127*(7 + 11)) 1.4 | (14/127*(7 + 11)) 0.6 |
(26/177) 14.7 | (20/177) 11.3 | (26/177*(5 + 11)) 0.9 | (20/177*(5 + 11)) 0.7 |